白花丹素衍生物Pln-7-co(oAc)体外抗肿瘤作用研究

广西师范大学学报（自然科学版） ›› 2013, Vol. 31 ›› Issue (1): 67-71.

白花丹素衍生物Pln-7-co(oAc)体外抗肿瘤作用研究

彭艳^1,2, 蔡乐靖¹, 周远华¹, 黎智¹, 刘仁路¹, 仲辉², 张国海²

1.广西师范大学生命科学学院,广西桂林541004;
2.广西师范大学化学化工学院,广西桂林541004

收稿日期:2012-07-06 出版日期:2013-03-20 发布日期:2018-11-26
通讯作者: 张国海(1984—),男,山东聊城人,广西师范大学教师。E-mail:zhangguohaiwansui@126.com
基金资助:
973计划前期研究专项(2011CB512005);广西自然科学基金研究生创新项目(2011106020710M55);药用资源化学与药物分子工程教育部重点实验室课题(CMEMR2012-A12,CMEMR2012-A15)

In vitro Anti-tumor Effect of Plumbagin Derivative Pln-7-co(oAc)

PENG Yan^1,2, CAI Le-jing¹, ZHOU Yuan-hua¹, LI Zhi¹, LIURen-lu¹, ZHONG Hui², ZHANG Guo-hai²

1.College of Life Science,Guangxi Normal University,Guilin Guangxi 541004,China;
2.College of Chemistry and Chemical Engineering,Guangxi Normal University,Guilin Guangxi 541004,China

Received:2012-07-06 Online:2013-03-20 Published:2018-11-26

摘要/Abstract

摘要： 本文以人肺癌NCI-H460、A549,肝癌BEL-7404,胃癌MCG-803细胞株以及正常肝细胞HL-7702作为受试细胞,分别采用MTT比色法、qPCR技术检测白花丹素衍生物(Pln-7-co(oAc))对细胞增殖的抑制作用以及对抑癌基因LRRC3B mRNA表达量的影响。结果显示,在10 μmol/L药物的作用下Pln-7-co(oAc)对NCI-H460细胞增殖的抑制率达到86.68%±2.89%,明显高于A549(59.56%±9.00%),肝癌BEL-7404(-7.24%±2.93%),胃癌MCG-803(15.27%±5.87%)。在IC₅₀测试实验中,Pln-7-co(oAc)对NCI-H460细胞株的增殖抑制作用呈现很好的剂量依赖关系,其IC₅₀值低至(4.85±0.61) μmol/L,明显优于阳性药物易瑞沙Iressa(20.17±2.15) μmol/L,LRRC3B mRNA的相对表达量明显升高。

关键词: NCI-H460, 白花丹素衍生物, 细胞增殖, 抑癌基因LRRC3B

Abstract: The anti-tumor effectin vitro of plumbagin derivative (Pln-7-co(oAc)) is investigated.Human lung cancer cell lines (NCI-H460,A549),human liver cancer cell line BEL-7404,human gastric cancer cell line MCG-803 andhuman normal liver cell line HL-7702 were served as the tested cells.The cellproliferation inhibition rates of Pln-7-co(oAc) were detected by MTT colorimetricassay.The relative expression of LRRC3B mRNA after Pln-7-co(oAc) treated wastested by qPCR.The inhibition rate of Pln-7-co(oAc) on NCI-H460 cells (86.68%±2.89%) was much higher than that on A549 cells (59.56%±9.00%),BEL-7404 cells (-7.24%±2.93%),MCG-803 cells (15.27%±5.87%) at a 10 μmol/L concentration.In IC₅₀ test,the inhibition rate of Pln-7-co(oAc) on NCI-H460 cells showed a good dose dependency with IC₅₀ value as low as (4.85±0.61) μmol/L,which was significantly better than the positive drug Iressa (20.17±2.15) μmol/L.The relative expressionofLRRC3B mRNA of Pln-7-co(oAc) group markedly increased compared with that of the control group.

Key words: NCI-H460, plumbagin derivative, cell proliferation, LRRC3B

中图分类号:

R284.3

彭艳, 蔡乐靖, 周远华, 黎智, 刘仁路, 仲辉, 张国海. 白花丹素衍生物Pln-7-co(oAc)体外抗肿瘤作用研究[J]. 广西师范大学学报（自然科学版）, 2013, 31(1): 67-71.

PENG Yan, CAI Le-jing, ZHOU Yuan-hua, LI Zhi, LIURen-lu, ZHONG Hui, ZHANG Guo-hai. In vitro Anti-tumor Effect of Plumbagin Derivative Pln-7-co(oAc)[J]. Journal of Guangxi Normal University(Natural Science Edition), 2013, 31(1): 67-71.

参考文献

[1] LIU Yan-cheng,CHEN Zhen-feng,LIANG Hong,et al.Divalent later transition metal complexes of the traditional Chinese medicine (TCM) liriodenine:coordination chemistry,cytotoxicity and DNA binding studies[J].Dalton Trans,2009,48:10813-10823.
[2] 陈振锋,彭艳,梁宏,等.基于中药活性成分的金属基抗肿瘤药物前期研究[J].化学进展,2009,21(5):929-933.
[3] KIM M,KIM J H,JANG H R,et al.LRRC3B,encoding a leucine-richrepeat-containing protein,is a putative tumor suppressor gene in gastric cancer[J].CancerRes,2008,68:147-155.
[4] 武明花,李小玲,李桂源.脑组织特异性基因/脑胶质瘤抑瘤基因LRRC4的功能研究进展[J].生物化学与生物物理进展,2007,34(12):1234-1239.
[5] 王洁如,李小玲,范松清,等.LRRC4基因表达能降低胶质母细胞瘤细胞系U251的生长和成瘤潜能[J].癌症,2003,9:897-902.
[6] CHEN Xin,LEUNG S Y,YUEN S T,et al.Variation in gene expressionpatterns in human gastric cancers[J].Mol Biol Cell,2003,14:3208-3215.
[7] RICHARDSON A L,WANG Z C,DE NICOLO A,et al.X chromosomal abnormalities in basal-like human breast cancer[J].Cancer Cell,2006,9:121-132.
[8] BIANCHINI M,LEVY E,ZUCCHINI C,et al.Comparative study of geneexpressionby cDNA microarray in human colorectal cancer tissues and normal mucosa[J].Int J Oncol,2006,29:83-94.
[9] LAPOINTE J,LI Chun-de,HIGGINS J P,et al.Gene expression profilingidentifies clinically relevant subtypes of pros-tate cancer[J].Proc Natl Acad Sci USA,2004,101:811-816.
[10] SUBHASH P,PRASAD D,MUJAHID Y,et al.Perspectives on medicinal properties of plumbagin and its analogs[J].Med Res Rev,2010,32:1131-1158.

Metrics

Viewed

Full text

Abstract

Cited

Shared

Discussed